For the millions living with schizophrenia-spectrum or bipolar-1 disorders, antipsychotic medications routinely cause metabolic harm — weight gain, insulin resistance, and pre-diabetes — while offering incomplete symptom control. A dietary intervention that addresses both problems simultaneously would represent a meaningful clinical advance, and this trial offers the first randomized evidence that a ketogenic diet might do exactly that.
In this 58-participant RCT published in Schizophrenia Bulletin, individuals were assigned to either a ketogenic diet or their usual eating pattern for one month, with a subset extending to four months. Those following the ketogenic protocol achieved measurable nutritional ketosis and showed statistically significant reductions in HbA1c and insulin resistance relative to controls, alongside weight loss. Critically, the four-month completers demonstrated improvements across positive symptoms, negative symptoms, depression, and cognitive performance, all reaching p-values below 0.001. Perhaps the most mechanistically telling finding: elevated blood ketone concentrations correlated directly with improvements in pre-diabetic markers and depressive symptoms — yet weight loss itself did not drive these metabolic or psychiatric gains, pointing toward ketone-mediated biology rather than caloric deficit as the operative mechanism.
This finding sits within an emerging literature connecting metabolic dysfunction to psychiatric pathophysiology — sometimes framed as a "metabolic psychiatry" paradigm — where mitochondrial energy metabolism, neuroinflammation, and glucose dysregulation are proposed as convergent drivers of psychosis. Ketones provide an alternative cerebral fuel and carry anti-inflammatory and GABA-modulating properties that plausibly explain the symptom signal here. However, several limitations warrant caution: the sample is small (n=58 randomized, only 25 completing four months), the extension phase was not fully randomized, and one month is a brief window. Adherence to ketogenic diets in outpatient psychiatric populations is historically challenging, and longer, larger trials with active dietary control groups are needed before clinical translation. Nonetheless, for an evidence-poor therapeutic area, this is an incremental but genuinely important proof-of-concept.